Quick Answer
Humacyte, Inc. reported Stockholders Equity of $3.11 million for fiscal year 2025.
Humacyte, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.11M | +105.9% |
| 2024 | -$52.67M | -488.8% |
| 2023 | $13.55M | -88.4% |
| 2022 | $116.93M | -4.3% |
| 2021 | $122.17M | +134.9% |
| 2020 | -$350.32M | -21.3% |
| 2019 | -$288.79M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.75M | +92.5% | -217.3% |
| June 30, 2025 | $4.05M | +114.3% | -88.8% |
| March 31, 2025 | $36.04M | +37.8% | +168.4% |
| December 31, 2024 | -$52.67M | -488.8% | +17.3% |
| September 30, 2024 | -$63.72M | -272.3% | -125.3% |
| June 30, 2024 | -$28.29M | -146.3% | -208.2% |
| March 31, 2024 | $26.15M | -68.1% | +93.1% |
| December 31, 2023 | $13.55M | -88.4% | -63.4% |
- Humacyte, Inc. showed an increase of +105.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Humacyte, Inc.’s stockholders equity has grown by 101.1% (from -$288.79 million to $3.11 million).
- The most recent figure is from Humacyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: